Antiviral & Antimicrobial Countermeasures Discovery and Development Core

项目摘要 所提出的抗病毒和抗微生物对策发现和开发核心（本文 缩写为A2 CD 2C）将促进以发现和/或开发为目标的生物医学研究 预防或治疗人类生物安全3级（BSL-3）病原体的对策，或 BSL-2病原体，要求选择代理控制。A2 CD 2C将利用最先进的技术 小分子设备（1）筛选，（2）成像，（3）液相色谱-质谱 (LCMS/MS）服务和（4）组织学。该核心将被安置在UTHSC区域生物安全壳内 BSL-3空间的RBL实验室。A2 CD 2C的重要性在于它提供了一种有效的、集成的、 全面的平台，将促进从最初发现阶段到临床前的研究 在BSL-3安全壳内进行开发。A2 CD 2C在RBL网络中是独一无二的，其重点是提供 在BSL-3中对感染的、处理的动物组织进行LC-MS研究，以提供急需的感染部位信息。 治疗剂在感染部位的暴露，从而提供重要的药效学信息 进行临床前评估。 A2 CD 2C的主要使命是维持、改善和扩大我们在药物方面的RBL支持服务。 发现和开发，重点是药物药效学，即如何和多少药物 暴露影响病原体存活。我们提出了三个目标，以实现在这里：目标1。保持 A2 CD 2C药物发现和开发的支持服务;目标2。改善A2 CD 2C支持服务 药物发现和开发;以及目标3。扩大A2 CD 2C在药物成像方面的支持服务 发现和发展。

PROJECT ABSTRACT The proposed Antiviral & Antimicrobial Countermeasures Discovery & Development Core (herein abbreviated as A2CD2C) will facilitate biomedical research targeted toward the discovery and/or development of countermeasures for prophylactic or therapeutic treatment of human biosafety level 3 (BSL-3) pathogens or BSL-2 pathogens that mandate select agent control. The A2CD2C will enable this research using state-of-the-art equipment for small molecule (1) screening, (2) imaging, (3) liquid chromatography-mass spectrometry (LCMS/MS) services and (4) histology. The core will be housed within the UTHSC Regional Biocontainment Laboratory (RBL) in BSL-3 space. The A2CD2C is significant in that it provides an efficient, integrated, comprehensive platform that will facilitate studies from the initial discovery phase through pre-clinical development within BSL-3 containment. The A2CD2C is unique within the RBL network in its focus on providing LC-MS studies for infected, treated animal tissues in BSL-3 to provide much needed information of the site of exposure of the therapeutic at the site of infection and thereby providing important pharmacodynamic information required for preclinical assessment. The major mission of the A2CD2C is to maintain, improve and expand our RBL support services in drug discovery and development with a focus on drug pharmacodynamics in terms of how and how much drug exposure impacts pathogen survival. We propose three objectives to achieve herein: Objective 1. To maintain A2CD2C support services in drug discovery and development; Objective 2. To improve A2CD2C support services in drug discovery and development; and Objective 3. To expand A2CD2C support services in imaging in drug discovery and development.